Nuformix plc Market Cap ($33.98K)
Market Cap & Net Worth: Nuformix plc (NFX)
Nuformix plc market cap. Nuformix plc (LSE:NFX) has a market capitalization of $33.98K (GBX279.24 Million) as of November 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31730 globally and #1231 in its home market, demonstrating a 7.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuformix plc's stock price GBX0.11 by its total outstanding shares 2609749368 (2.61 Billion). Also see NFX cash flow conversion for how efficiently the company converts equity into cash flow.
Nuformix plc Market Cap History (2015–2026)
Nuformix plc market cap history from 2015 to 2026. Data shows change from $714.44K to $33.98K (-25.47% CAGR). Check NFX stock price for real-time trading data and today's change.
Nuformix plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuformix plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Nuformix plc (NFX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.16x
Nuformix plc's market cap is 2.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $666.82K | $15.00K | -$1.84 Million | 44.45x | N/A |
| 2019 | $2.84 Million | $610.00K | -$1.66 Million | 4.66x | N/A |
| 2020 | $857.33K | $535.00K | -$756.38K | 1.60x | N/A |
| 2021 | $341.35K | $195.55K | -$1.25 Million | 1.75x | N/A |
| 2022 | $107.96K | $50.00K | -$1.11 Million | 2.16x | N/A |
Competitor Companies of NFX by Market Capitalization
Companies near Nuformix plc in the global market cap rankings as of November 3, 2026. Also see how large is Nuformix plc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Nuformix plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Nuformix plc (2015–2026)
Market capitalization of Nuformix plc from 2015 to today. Between 2015 and today, Nuformix plc's market cap moved from $714.44K to $ 33.98K, with a yearly change of -25.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX33.98K | -58.04% |
| 2025 | GBX80.97K | +436.84% |
| 2024 | GBX15.08K | -85.38% |
| 2023 | GBX103.20K | -4.41% |
| 2022 | GBX107.96K | -68.37% |
| 2021 | GBX341.35K | -60.19% |
| 2020 | GBX857.33K | -69.83% |
| 2019 | GBX2.84 Million | +326.19% |
| 2018 | GBX666.82K | -30.00% |
| 2017 | GBX952.59K | -14.29% |
| 2016 | GBX1.11 Million | +55.56% |
| 2015 | GBX714.44K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Nuformix plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.98K USD |
| MoneyControl | $33.98K USD |
| MarketWatch | $33.98K USD |
| marketcap.company | $33.98K USD |
| Reuters | $33.98K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more